Invivyd, Inc. (IVVD) stock
IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.51−0.03 (-4.67%)
Close on Nov 17, 2026Market cap $151.09MP/E –Yield –
Invivyd total assets
Total assets on the balance sheet at the end of each period.
Invivyd's total assets was $218.88M at Jun 30, 2026. For fiscal 2025 it was $276.88M, up 113.8% from the year before. The highest annual figure on record is $620.09M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $276.88M | +113.8% |
| FY2024 | Dec 31, 2024 | $129.52M | -43.5% |
| FY2023 | Dec 31, 2023 | $229.18M | -40.2% |
| FY2022 | Dec 31, 2022 | $383.17M | -38.2% |
| FY2021 | Dec 31, 2021 | $620.09M | +428.3% |
| FY2020 | Dec 31, 2020 | $117.38M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $218.88M | +145.6% |
| Q1 FY2026 | Mar 31, 2026 | $241.74M | +133.0% |
| Q4 FY2025 | Dec 31, 2025 | $276.88M | +113.8% |
| Q3 FY2025 | Sep 30, 2025 | $139.16M | -14.1% |
| Q2 FY2025 | Jun 30, 2025 | $89.14M | -49.7% |
| Q1 FY2025 | Mar 31, 2025 | $103.74M | -51.9% |
| Q4 FY2024 | Dec 31, 2024 | $129.52M | -43.5% |
| Q3 FY2024 | Sep 30, 2024 | $161.92M | -41.1% |
| Q2 FY2024 | Jun 30, 2024 | $177.35M | -43.8% |
| Q1 FY2024 | Mar 31, 2024 | $215.47M | -38.5% |
| Q4 FY2023 | Dec 31, 2023 | $229.18M | -40.2% |
| Q3 FY2023 | Sep 30, 2023 | $274.92M | -35.3% |
| Q2 FY2023 | Jun 30, 2023 | $315.41M | -34.9% |
| Q1 FY2023 | Mar 31, 2023 | $350.56M | -37.0% |
| Q4 FY2022 | Dec 31, 2022 | $383.17M | -38.2% |
| Q3 FY2022 | Sep 30, 2022 | $424.75M | -38.1% |
| Q2 FY2022 | Jun 30, 2022 | $484.61M | +21.8% |
| Q1 FY2022 | Mar 31, 2022 | $556.27M | +373.9% |
| Q4 FY2021 | Dec 31, 2021 | $620.09M | – |
| Q3 FY2021 | Sep 30, 2021 | $686.27M | – |
| Q2 FY2021 | Jun 30, 2021 | $397.99M | – |
| Q4 FY2020 | Dec 31, 2020 | $117.38M | – |
See a number that looks wrong?